DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effect of Acupuncture to Endothelial Dysfunction Induced by Ischemia-reperfusion Injury

Information source: Kyunghee University Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Active acupuncture (Device); Sham acupuncture (Device); Euglucon 5mg (Drug); Celebrex 200mg (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Kyunghee University Medical Center

Official(s) and/or principal investigator(s):
Weon Kim, Principal Investigator, Affiliation: Kyunghee University Medical Center

Overall contact:
Weon Kim, Professor, Phone: 82-2-958-8176, Email: mylovekw@hanmail.net

Summary

Some studies suggest that acupuncture improve flow mediated dilation (FMD) that represents endothelial function, but no study has investigated whether acupuncture protects against ischemia and reperfusion (IR)-induced endothelial dysfunction in humans. This is a prospective crossover study clinical trial. In the first crossover study, 20 healthy nonsmoking volunteers (25 to 40 years old) will be randomly assigned to acupuncture or control. Endothelium-dependent, FMD of the brachial artery will be measured before and after IR (15 minutes of ischemia at the level of the proximal upper arm followed by 15 minutes of reperfusion). Acupuncture will be performed from 10 minute after ischemia till the end time of reperfusion for 20 minutes. In the second single arm study, 16 volunteers are administered oral 5mg glibenclamide two hours before IR injury (n=8) or selective cox-2 inhibitor celecoxib 200mg twice a day for 5 days to know what mechanism is responsible for acupuncture effect on IR injury. FMD measurements and acupuncture intervention during IR injury are same as above mentioned.

Clinical Details

Official title: Effect of Acupuncture to Endothelial Dysfunction Induced by Ischemia-reperfusion Injury Via Adenosine Triphosphate-sensitive Potassium Channels or Prostaglandin Pathway

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: The difference of endothelial function

Secondary outcome: The difference of endothelial function

Eligibility

Minimum age: 25 Years. Maximum age: 40 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- healthy volunteer age 25 to 40 years

- non-smoker

Exclusion Criteria:

- hypertension (>140/90 mmHg), diabetes any cardiovascular disease kidney disease

thyroid disease cerebrovascular disease liver disease (bilirubin level >2 mg/dl) pregnancy body mass index >25 kg/m2

Locations and Contacts

Weon Kim, Professor, Phone: 82-2-958-8176, Email: mylovekw@hanmail.net

Kyung Hee University Medical Center, Seoul 130-701, Korea, Republic of; Recruiting
Weon Kim, Professor, Phone: 82-2-958-8176, Email: mylovekw@hanmail.net
Additional Information

Starting date: May 2014
Last updated: September 29, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017